📊 NBY Key Takeaways
Is NBY a Good Investment? Thesis Analysis
Stablecoin Development Corp exhibits terminal financial distress with negative stockholders' equity of -$23.2M, indicating technical insolvency. The company is burning $8.4M annually in operating losses against only $521K in declining revenue, creating a fundamentally unsustainable business model that will exhaust its $8M cash reserve within 12 months absent significant operational transformation or external capital injection.
Why Buy NBY? Key Strengths
- Maintains $8.0M cash reserve providing short-term liquidity buffer
- Minimal capital expenditure requirements ($0) reduces ongoing investment needs
- Recent insider activity suggests management engagement despite distress
NBY Investment Risks to Consider
- Negative stockholders' equity of -$23.2M represents technical insolvency with liabilities exceeding assets by $22.9M
- Operating cash burn of -$8.4M annually against $521K revenue is mathematically unsustainable; cash runway approximately 12 months
- Gross margin of 8.1% indicates severe operational inefficiency; unit economics appear broken
- Revenue declining 6.4% YoY demonstrates deteriorating market traction or demand
- Massive net losses (-$22.1M) and operating losses (-$8.4M) on minimal revenue base signal fundamental business model failure
- EPS improvement amid revenue decline and increased losses suggests dilutive capital raises likely
Key Metrics to Watch
- Cash burn rate and remaining cash runway (critical near-term solvency indicator)
- Revenue stabilization and gross margin improvement (currently unsustainable)
- Restructuring or capital raise announcements (required for survival)
- Change in total liabilities and stockholders' equity trajectory (insolvency indicator)
NBY Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.60x current ratio provides a solid financial cushion.
NBY Profitability Ratios
NBY vs Healthcare Sector
How NovaBay Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NBY Overvalued or Undervalued?
Based on fundamental analysis, NovaBay Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NBY Balance Sheet & Liquidity
NBY 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: NovaBay Pharmaceuticals, Inc.'s revenue has declined by 16% over the 5-year period, indicating business contraction. The most recent EPS of $-12.68 indicates the company is currently unprofitable.
NBY Growth Metrics (YoY)
NBY Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.2M | $-0.22 |
| Q3 2024 | $2.4M | -$1.2M | N/A |
| Q2 2024 | $2.4M | -$1.6M | N/A |
| Q1 2024 | $2.3M | -$1.7M | N/A |
| Q3 2023 | $3.3M | -$111.0K | N/A |
| Q2 2023 | $3.7M | -$111.0K | N/A |
| Q1 2023 | $3.1M | -$111.0K | N/A |
| Q3 2022 | $2.3M | -$111.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NBY Capital Allocation
NBY SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for NovaBay Pharmaceuticals, Inc. (CIK: 0001389545)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NBY
What is the AI rating for NBY?
NovaBay Pharmaceuticals, Inc. (NBY) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NBY's key strengths?
Claude: Maintains $8.0M cash reserve providing short-term liquidity buffer. Minimal capital expenditure requirements ($0) reduces ongoing investment needs.
What are the risks of investing in NBY?
Claude: Negative stockholders' equity of -$23.2M represents technical insolvency with liabilities exceeding assets by $22.9M. Operating cash burn of -$8.4M annually against $521K revenue is mathematically unsustainable; cash runway approximately 12 months.
What is NBY's revenue and growth?
NovaBay Pharmaceuticals, Inc. reported revenue of $521.0K.
Does NBY pay dividends?
NovaBay Pharmaceuticals, Inc. pays dividends, with $4.8M distributed to shareholders in the trailing twelve months.
Where can I find NBY SEC filings?
Official SEC filings for NovaBay Pharmaceuticals, Inc. (CIK: 0001389545) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NBY's EPS?
NovaBay Pharmaceuticals, Inc. has a diluted EPS of $0.76.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NBY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, NovaBay Pharmaceuticals, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NBY stock overvalued or undervalued?
Valuation metrics for NBY: ROE of N/A (sector avg: 15%), net margin of -4,249.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NBY stock in 2026?
Our dual AI analysis gives NovaBay Pharmaceuticals, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NBY's free cash flow?
NovaBay Pharmaceuticals, Inc.'s operating cash flow is $-8.4M, with capital expenditures of $0.0. FCF margin is -1,618.0%.
How does NBY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,249.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 7.60 (avg: 2).